OmniAb
OmniAb, Inc. licenses proprietary transgenic antibody discovery platforms — including OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniUltra — paired with xPloration single B-cell screening and Ab Initio antigen design, to pharmaceutical and biotechnology partners developing next-generation therapeutics across multiple modalities.
- Company typePublic
- Founded2022
- HeadquartersEmeryville, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What OmniAb does
OmniAb, Inc. provides pharmaceutical and biotechnology companies with access to a proprietary antibody discovery platform built on multiple genetically engineered transgenic animal systems — including OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra, OmniFlic, OmniClic, and Omni*dAb* — that produce fully human antibody repertoires across diverse host species and structural motifs. These biological intelligence (BI)-powered repertoires are paired with the xPloration high-throughput microfluidic single B-cell screening platform, the Ab Initio computational antigen design capability, in silico discovery tools operated from its Oro Valley, AZ center, Fc-silencing antibody optimization, and a dedicated ion channel and transporter research capability (Icagen) in Durham, NC. The platform supports discovery across multiple therapeutic modalities including traditional antibodies, bispecifics, antibody-drug conjugates, CAR-T, radioligands, and picobodies, with three OmniAb-derived antibodies already securing regulatory approvals (zimberelimab and sugemalimab in China; TECVAYLI in the EU).
OmniAb operates a sales-led, enterprise licensing business model, distributing its technology through direct business development relationships with biopharma partners and co-discovery engagements. Revenue is generated through upfront license fees, milestone payments triggered by partner program achievements (such as the $10M TECVAYLI European commercial sale milestone), service fees for antibody discovery work performed, and royalties on commercial sales for agreements that include them (notably, the TECVAYLI/Janssen agreement does not include royalties). Pricing is quote-based and multi-year, with terms customized per partner. The customer base spans 107 active partners running 409 active programs, of which 32 are in clinical development or commercialization, distributed across large pharma (Janssen, Teva, Merck KGaA), mid-cap and emerging biotechs (Immunovant, CStone, Gloria Biosciences, HanAll, Veraxa, Mabtrx), and academic institutions (Memorial Sloan Kettering, Dana Farber).
The company originated as the antibody discovery business of Ligand Pharmaceuticals and became an independent publicly traded entity in November 2022 via a Reverse Morris Trust spin-off and business combination with Avista Public Acquisition Corp. II, listing on Nasdaq under ticker OABI at an $850 million pre-money equity valuation. Headquartered in Emeryville, California, with additional R&D sites in Durham, NC and Oro Valley, AZ, OmniAb reported FY2025 revenue of $18.7M (a decline from $26.4M in FY2024) followed by Q1 2026 revenue of $14.4M representing 243% YoY growth, prompting management to raise full-year 2026 guidance to $28–33M. The company is unprofitable, with a FY2025 net loss of $64.8M, but held approximately $60M in cash with no debt as of September 2025 and reduced cash burn by approximately 25% year-over-year.
OmniAb firmographics
Firmographics- Name
- OmniAb
- Legal name
- OmniAb, Inc.
- Website
- https://omniab.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- OmniAb, Inc. licenses proprietary transgenic antibody discovery platforms — including OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniUltra — paired with xPloration single B-cell screening and Ab Initio antigen design, to pharmaceutical and biotechnology partners developing next-generation therapeutics across multiple modalities.
- Ownership category
- akta.pro rank
OmniAb industry classification
Industry- Product category
- Therapeutic Antibody Discovery
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where OmniAb is headquartered
LocationHeadquarters
- HQ city
- Emeryville
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
OmniAb business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Upfront License Fees: One-time upfront payments received upon execution of license agreements with partners accessing OmniAb's antibody discovery technology. Recorded as license revenue when recognized.
- Milestone Payments: Contractual milestone payments triggered by partner program achievements such as regulatory approvals (e.g., $10M milestone upon first commercial sale of TECVAYLI in Europe) and clinical/development progression. Milestone revenue drove Q1 2026 revenue of $14.4M, a 243% increase year-over-year.
- Service Revenue: Revenue earned from performing antibody discovery and related research services for partners using OmniAb's platforms and capabilities. Decreased in 2025 versus 2024.
- Royalties on Commercial Sales: Recurring royalty revenue tied to commercial sales of approved OmniAb-derived therapeutic products by partners. Note: not all license agreements include royalties (e.g., the OmniAb/Janssen license for TECVAYLI does not include royalty payments to OmniAb). Royalty revenue represents a future, milestone-driven stream as more partnered programs reach commercialization.
- xPloration® Partner Access Program Fees: Program introduced in May 2025 enabling partners to access xPloration's high-throughput single B-cell screening capabilities in their own laboratories; expected to generate service/program fees.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based technology licensing and discovery services |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
OmniAb product offering
Product offeringCore offering
OmniAb licenses an integrated therapeutic antibody discovery platform to pharmaceutical and biotechnology partners. Its foundation is a suite of proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra and Omni*dAb*, plus OmniFlic/OmniClic for bispecifics — that produce diverse fully human antibody repertoires. These are paired with the xPloration high-throughput single B-cell screening platform, Ab Initio computational antigen design, in silico NGS repertoire mining, Fc-silencing optimization, and an established ion channel/transporter (Icagen) capability to deliver end-to-end antibody discovery across modalities including bispecifics, ADCs, CAR-T, radioligands and picobodies.
Product overview
OmniAb offers a single integrated therapeutic antibody discovery platform rather than standalone point products. At the core are multiple proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, Omni*dAb*, OmniUltra, and OmniTaur — which together generate diverse fully human antibody repertoires, with OmniFlic and OmniClic extending this into common-light-chain bispecific applications. These biological intelligence (BI)-powered repertoires are paired with the xPloration high-throughput single B-cell screening platform, the Ab Initio computational Antigen Design module, the broader In Silico Technologies suite, Fc-Silencing Technology for Antibody Optimization, and an Ion Channel and Transporter (Icagen) capability, all delivered to partners through licensing and services agreements plus the xPloration Partner Access Program.
Differentiator
Problem solved
Functional benefit
Brands
- OmniUltra: Transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework, extending into peptide therapeutics for bispecifics, CAR-T, radioligands, and picobody discovery; launched December 2025.
- OmniRat
- OmniMouse
- OmniChicken
- OmniTaur
- Omni*dAb*
- OmniFlic
- OmniClic
- xPloration
Quantifiable outcome
- 243% year-over-year revenue increase in Q1 2026 ($14.4M)
- +5 more outcomes
Companies that use OmniAb
Customer profileNamed customers16 records
Segments3 records
Ideal customer profiles3 records
OmniAb technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability7 records
Feature14 records
OmniAb partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core, major, transactional, minor and flagship.
- Ernst & Young LLPcoreRatified as OmniAb's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026 Annual Meeting of Shareholders, with 102,163,551 votes in favor and only 112,653 votes against.
- ImmunovantmajorImmunovant is a partner developing OmniAb-discovered antibodies including batoclimab (Phase 3 in thyroid eye disease) and IMVT-1402 (Phase 2/3). Reported R&D progress in Q4 2025 earnings; topline data expected through 2026-2027. Phase 3 failure of batoclimab in thyroid eye disease did not impact OmniAb's analyst outlook.
- Teva Pharmaceutical IndustriesmajorTeva is a partner with program TEV-408 progressing through Phase 1/2 trials; reported R&D progress in Q4 2025 earnings and subsequent quarters with topline data expected.
- Merck KGaAmajorMerck KGaA is a partner with an OmniAb-derived program progressing through R&D; reported R&D progress in Q4 2025 earnings and subsequent quarters.
- Mabtrx Biosciences (subsidiary of AMVKG LS, a JV between ArrowMark Partners and Viking Global Investors)coreTechnology license and services agreement for antibody discovery using OmniAb's technology. Revenue, potential equity, and royalties are involved in the arrangement. Mabtrx Biosciences is a newly-formed incubated company of ArrowMark Partners and Viking Global Investors.
- Latham & Watkins LLPtransactionalLatham & Watkins LLP advised OmniAb on the $30 million private placement announced August 2025. Legal counsel role in capital markets transaction.
- Veraxa Biotech AGcoreCo-discovery alliance to develop a novel bispecific antibody-drug conjugate (bsADC) program targeting solid tumors. Combines OmniAb's transgenic antibody discovery technology with Veraxa's proprietary ADC linker and conjugation expertise. Resulting bsADC program is jointly owned by both parties, with shared future revenues from development, licensing, and commercialization. Described as Veraxa's second major strategic collaboration within six months.
- Chiome BioscienceminorCollaboration on antibody research using OmniAb's antibody discovery technology. Reported as a research collaboration agreement; details of the partnership scope and economics were not disclosed in the available source.
- DAAN BiominorSigned a new platform license agreement with OmniAb in 2024 for antibody discovery; one of multiple new partner agreements cited by CEO Matt Foehr as a record year for deal flow.
- Topaz TherapeuticsminorSigned a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings.
- HanAll BiopharmaminorSigned a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings in 2024.
- 92BiominorSigned a new platform license agreement with OmniAb in 2024 for antibody discovery; part of a wave of new partner signings.
- Memorial Sloan Kettering Cancer CenterminorSigned a new platform license agreement with OmniAb in 2024 for antibody discovery; one of the academic/research institution partners disclosed in 2024 deal flow.
- Redwood BioscienceminorEntered a joint agreement with OmniAb in 2024 for antibody research collaboration; one of the partnerships cited as supporting record deal flow in 2024.
- Janssen Biotech (Johnson & Johnson)flagshipJanssen discovered TECVAYLI (teclistamab) — a BCMA x CD3 bispecific antibody — using OmniAb's OmniRat antibody discovery technology. TECVAYLI received European Commission conditional marketing authorization in August 2022 (first European approval of an OmniAb-derived antibody and first OmniAb-derived bispecific). OmniAb is eligible for a $10M milestone payment upon first commercial sale in the UK, Italy, Germany, France, or Spain. Note: the license agreement with CNA Development LLC does not include royalty payments to OmniAb.
- Ligand PharmaceuticalsflagshipOmniAb was spun off from Ligand Pharmaceuticals through a Reverse Morris Trust transaction with Avista Public Acquisition Corp. II (APAC), closing on November 1, 2022 with regular-way trading beginning November 2, 2022 on Nasdaq under ticker 'OABI'. Ligand contributed $15M to OmniAb; Ligand shareholders received 100% of Ligand's shares in OmniAb through a tax-free distribution. Ligand shareholders were expected to own approximately 75% of the combined entity.
- CStone PharmaceuticalsmajorCStone developed sugemalimab (Cejemly), an anti-PD-L1 monoclonal antibody discovered using OmniAb's OmniRat platform. Received NMPA approval in China for first-line treatment of metastatic NSCLC in combination with chemotherapy in December 2021; subsequent clinical programs in R/R ENKTL, gastric, and esophageal cancers.
- Gloria BiosciencesmajorGloria Biosciences received NMPA approval in China for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody, for recurrent or refractory classical Hodgkin's lymphoma — the first regulatory approval of an OmniAb-derived antibody. GloriaBio holds development and commercialization rights in China via a sublicense with Wuxi Biologics Ireland Limited.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
OmniAb competitors and assessment
Company assessmentDirect peers
- Adimab: Adimab is a private antibody discovery platform company offering yeast- and mammalian-based discovery services to biopharma partners under a similar licensing/services/milestone model. Most direct functional comparable to OmniAb in business model and customer base.
- AbCellera Biologics: AbCellera is a public antibody discovery platform (Nasdaq: ABCL) that uses single B-cell screening, similar to OmniAb's xPloration, and licenses to pharma partners. Directly comparable in target market (biopharma antibody discovery) and business model (licensing + milestones + royalties).
- AnaptysBio: AnaptysBio is a clinical-stage antibody company with an in-house discovery platform that it has also historically partnered with pharma. Comparable as a publicly traded antibody-discovery platform company serving the same biopharma partner base.
Broad incumbents
- Ligand Pharmaceuticals: Ligand is OmniAb's former parent and operates a similar technology-licensing and royalty business model across multiple platforms (Captisol, OmniAb legacy, others). Comparable as a publicly traded platform-licensing biotech, though more diversified beyond antibodies.
- Charles River Laboratories: Charles River offers a broad suite of CRO and discovery services, including biologics and antibody-related capabilities (e.g., Distributed Bio, Retrogenix). It is a comparable enterprise-scale services provider to biopharma, though antibody discovery is one of many service lines.
- WuXi Biologics: WuXi Biologics is a global contract biologics manufacturer and discovery services provider. It overlaps with OmniAb's biopharma services customer base and serves as a broad incumbent in the biologics discovery/CDMO space.
Emerging players
- Ginkgo Bioworks: Ginkgo is a public cell programming and biosecurity platform company. While not a direct antibody peer, it is comparable as a publicly traded platform-licensing biology business pursuing enterprise biopharma and broader life sciences customers.
- Generate Biomedicines: Generate is a privately held AI/ML-driven generative biology company developing programmable antibodies and peptides. Comparable as an emerging player in the antibody/peptide discovery space that could overlap with OmniUltra's peptide and next-generation modality ambitions.
- Crescendo Biologics: Crescendo is a private T cell engager and multi-modality antibody platform company (e.g., Humabody V_H). Comparable as an emerging player in next-generation antibody modalities (single-domain, bispecifics) that intersects with OmniAb's Omni*dAb* and bispecific platforms.
Others
- Bio-Techne: Bio-Techne is a publicly traded life sciences research tools and diagnostics company that supplies reagents, proteins, and antibodies to the same biopharma research customers. Comparable as an ecosystem enabler serving antibody discovery workflows, though not a direct platform competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
OmniAb social profiles
Digital presenceOmniAb compliance and trust
Trust signalCompliance5 records
OmniAb financial estimates
Financial estimateRevenue estimate
Valuation estimate
OmniAb leadership team
Management profileNumber of profiles
Profiles6 records
OmniAb subsidiaries and ownership
Company hierarchySubsidiaries1 record
OmniAb funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OmniAb M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OmniAb
What does OmniAb do?
OmniAb licenses an integrated therapeutic antibody discovery platform to pharmaceutical and biotechnology partners. Its foundation is a suite of proprietary transgenic animal platforms — OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniUltra and Omni*dAb*, plus OmniFlic/OmniClic for bispecifics — that produce diverse fully human antibody repertoires. These are paired with the xPloration high-throughput single B-cell screening platform, Ab Initio computational antigen design, in silico NGS repertoire mining, Fc-silencing optimization, and an established ion channel/transporter (Icagen) capability to deliver end-to-end antibody discovery across modalities including bispecifics, ADCs, CAR-T, radioligands and picobodies.
Is OmniAb a public or private company?
OmniAb is a public company. It is classified as public and is currently operating.
When was OmniAb founded?
OmniAb was founded in 2022. It employs 51 to 100 people.
Where is OmniAb based?
OmniAb is headquartered in Emeryville, United States, in the North America region.
How does OmniAb make money?
Five revenue lines are on record. Upfront License Fees are the primary driver. The others are milestone Payments, service Revenue, royalties on Commercial Sales and xPloration® Partner Access Program Fees.
Who are OmniAb's main competitors?
Direct peers on record are Adimab, AbCellera Biologics and AnaptysBio. Broad incumbents are Ligand Pharmaceuticals, Charles River Laboratories and WuXi Biologics. Emerging players are Ginkgo Bioworks, Generate Biomedicines and Crescendo Biologics. Bio-Techne is listed as an others.
Does OmniAb have an API?
No public API is recorded for OmniAb.
What industry is OmniAb in?
OmniAb's product category is Therapeutic Antibody Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 3254 and its SIC code is 2836.